Five things for pharma marketers to know: Tuesday, January 17, 2017

Five things for pharma marketers to know: Tuesday, January 17, 2017

Biogen to pay $1.25 billion for patents to MS drugs; Supreme Court to hear Novartis case over Zarxio delay; Merck KGaA inks big-data deal

Five things for pharma marketers to know: Friday, January 13, 2017

Five things for pharma marketers to know: Friday, January 13, 2017

CVS to sell generic EpiPen; FDA finalizes biosimilar naming rules; Pfizer wants to make a deal

GCI Health plants its flag in Philadelphia

GCI Health plants its flag in Philadelphia

The firm is sharing space in the City of Brotherly Love with healthcare media shop CMI.

Day 3 at JP Morgan: The move toward big data requires drugmakers to ask questions

Day 3 at JP Morgan: The move toward big data requires drugmakers to ask questions

There are dozens of players, including leaders like IBM Watson Health and Verily as well as smaller concerns, lining up to sell pharma access to some sort of data solution.

Five things for pharma marketers to know: Thursday, January 12, 2017

Five things for pharma marketers to know: Thursday, January 12, 2017

Trump says pharma is "getting away with murder"; Senate majority votes to repeal ACA; IBM Watson Health and FDA to study blockchain technology

Merck's Keytruda combo could edge out the competition

Merck's Keytruda combo could edge out the competition

Merck said the FDA accepted its submission of a Keytruda/chemotherapy combo drug and granted it Priority Review.

Day 2 at JP Morgan: Change is coming, but which drugmakers will stay on top?

Day 2 at JP Morgan: Change is coming, but which drugmakers will stay on top?

J&J's CEO may be right. Customers of all kinds are demanding change.

Five things for pharma marketers to know: Wednesday, January 11, 2017

Five things for pharma marketers to know: Wednesday, January 11, 2017

The FDA accepts Keytruda combo for review; Valeant offloads Dendreon and skincare brands; pharmacies feeling the squeeze from Express Scripts

Tonic Life promotes Stephanie DeViteri to MD

Tonic Life promotes Stephanie DeViteri to MD

DeViteri started in the newly created role this month.

Physicians group urges metformin rather than new drugs

Physicians group urges metformin rather than new drugs

The American College of Physicians said the costs of some new diabetes drugs do not always mean added benefits for patients.

Day 1 at JP Morgan: Pricing is top of mind for pharma CEOs

Day 1 at JP Morgan: Pricing is top of mind for pharma CEOs

The questions being asked about how drugs are priced are weighing heavily on pharma leaders, and they know the issue is not going away.

Five things for pharma marketers to know: Tuesday, January 10, 2017

Five things for pharma marketers to know: Tuesday, January 10, 2017

Illumina and IBM enter DNA sequencing partnership; J&J to outline price increases in new report; Egalet's opioid Arymo ER gets FDA approval

Ex-Guidemark CEO Matt Brown hangs out new shingle, Brand Mettle

Ex-Guidemark CEO Matt Brown hangs out new shingle, Brand Mettle

The new agency will focus on marketing goods and services to people 50 years of age and older.

MMC's Diana Littman on waiting for a decision after a pitch

MMC's Diana Littman on waiting for a decision after a pitch

She says her experience in consumer brands helps her push healthcare clients to be more creative.

Five things for pharma marketers to know: Monday, January 9, 2017

Five things for pharma marketers to know: Monday, January 9, 2017

Takeda to acquire Ariad for $4.6 billion, Merck pairs with Incyte for Keytruda combo drug collaboration; Sanofi announces autoimmune research deal

Five things for pharma marketers to know: Friday, January 6, 2017

Five things for pharma marketers to know: Friday, January 6, 2017

Judge halts Praluent sales; clinical-trial data for Diclegis in question; cancer drugs to make up larger portion of total drug spending

The FDA to study whether people can recognize misleading drug ads

The FDA to study whether people can recognize misleading drug ads

The agency has faced questions about how it regulates off-label communications.

Five things for pharma marketers to know: Thursday, January 5, 2017

Five things for pharma marketers to know: Thursday, January 5, 2017

Orexigen launches new campaign for weight-loss drug Contrave; Arena sells Belviq to Eisai; Alexion reportedly pushed for 'pull-in' sales

QuintilesIMS taps Staub as head of R&D solutions

QuintilesIMS taps Staub as head of R&D solutions

The merger of Quintiles and IMS Health closed in October.

Five things for pharma marketers to know: Wednesday, January 4, 2017

Five things for pharma marketers to know: Wednesday, January 4, 2017

Sanofi, Regeneron denied bid to overturn Amgen win in patent case; Abbott to close St. Jude deal; Gilead hires SVP of hematology and oncology

The FDA in 2016: By the numbers

The FDA in 2016: By the numbers

With 2016 in the rearview, here are four stats detailing how the FDA fared last year in enforcing regulations and approving new drugs.

How different generations form online "tribes"

How different generations form online "tribes"

Facebook and Instagram are the primary location for brands to engage with online tribes, while Raptr and PlayFire are a hit with boomers.

Five things for pharma marketers to know: Tuesday, January 3, 2017

Five things for pharma marketers to know: Tuesday, January 3, 2017

The FDA approves 22 new drugs in 2016; the Philippines orders Sanofi to stop Dengvaxia ads; new spinal muscular atrophy drug to cost $375,000

Five things for pharma marketers to know: Thursday, December 29, 2016

Five things for pharma marketers to know: Thursday, December 29, 2016

Gilead forms network to encourage access to hep.-C drugs; Dentsu CEO to resign following the suicide of a staffer; BI to divest animal-health products

MM&M's top health technology stories of 2016

MM&M's top health technology stories of 2016

We at MM&M found out just how much pharma marketers love a list. Here, read through the year's most-read technology stories.

Five things for pharma marketers to know: Wednesday, December 28, 2016

Five things for pharma marketers to know: Wednesday, December 28, 2016

Sanofi sues Novo over Tresiba marketing; the FDA issues two more untitled letters; U.S. health spending rose substantially from 1996 to 2013

MM&M's top stories of 2016

MM&M's top stories of 2016

Find out what stories generated the most interest among our readers.

Five things for pharma marketers to know: Tuesday, December 27, 2016

Five things for pharma marketers to know: Tuesday, December 27, 2016

Allergan's board endorses its social contract with patients; drugmakers that market painkillers are hiring DEA officials; the FDA approves new Biogen drug

Luxottica looks to 360 video to highlight childhood vision

Luxottica looks to 360 video to highlight childhood vision

When the vision company needed to demonstrate to parents the plight of children struggling to see, it turned to Olson 1to1 and a 360 video to tell the story.

Five things for pharma marketers to know: Thursday, December 22, 2016

Five things for pharma marketers to know: Thursday, December 22, 2016

Senate report said certain drugmakers act like hedge funds; ViiV to develop HIV prevention drug; lawmakers to replace ACA with "universal access"

Five things for pharma marketers to know: Wednesday, December 21, 2016

Five things for pharma marketers to know: Wednesday, December 21, 2016

GSK's two-drug combo for HIV has positive Phase-III results; the FDA approves glucose system that doesn't use finger pricking; Rite Aid to sell stores

The FDA issues two more enforcement letters this week

The FDA issues two more enforcement letters this week

The agency has sent nine untitled and warning letters so far this year.

CME providers use Facebook Live to educate doctors

CME providers use Facebook Live to educate doctors

A recent CME course using Facebook Live generated 34,000 views and 600 comments.

Five things for pharma marketers to know: Tuesday, December 20, 2016

Five things for pharma marketers to know: Tuesday, December 20, 2016

Biogen names new CEO; the FDA issues two warning letters; Allergan to acquire aesthetics firm

Drugmakers formalize patient roles as they work to define patient centricity

Drugmakers formalize patient roles as they work to define patient centricity

For years pharma has said it needs to be more focused on patients, has it delivered?

Five things for pharma marketers to know: Monday, December 19, 2016

Five things for pharma marketers to know: Monday, December 19, 2016

The FDA drops Chantix's black-box warning; hospitals try to reduce drug spending; AstraZeneca's head of oncology to depart

The next generation: Q&As with 3 agency staffers

The next generation: Q&As with 3 agency staffers

MM&M conducted Q&As with Stephanie Robinson, senior account manager, The Bloc; Jessica Hill, account supervisor, Ogilvy CommonHealth; and Austin Bald, account executive, TBWA\WorldHealth.

A look back: Q&As with Lester Barnett, C. Marshall Paul, and Steve Girgenti

A look back: Q&As with Lester Barnett, C. Marshall Paul, and Steve Girgenti

Read what they have to say about the defining moments and challenges in their careers.

Millennial staffers at agencies seek work-life balance and strong supervisors

Millennial staffers at agencies seek work-life balance and strong supervisors

Many young staffers agree one of the biggest challenges in their careers has been learning the delicate balance of when to speak up and when to listen.

MM&M launches Young Jurists program

MM&M launches Young Jurists program

We are looking for young professionals who are determined to develop their careers in healthcare advertising and marketing.

Five things for pharma marketers to know: Friday, December 16, 2016

Five things for pharma marketers to know: Friday, December 16, 2016

Allergan to settle allegations relating to speakers bureaus; Mylan launches generic version of the EpiPen; 20 states sue six drugmakers accused of price-fixing

Pfizer creates app for patients with depression

Pfizer creates app for patients with depression

The connection to Pristiq is not overt in the app's user interface, though Moodivator is featured on Pristiq's website.

Five things for pharma marketers to know: Thursday, December 15, 2016

Five things for pharma marketers to know: Thursday, December 15, 2016

Drugmakers promote new type of opioid with unproven results; Heritage execs charged for price-fixing generics; Pershing sells more Valeant shares

The FDA issues untitled letters to Sanofi and Celgene over distracting ads

The FDA issues untitled letters to Sanofi and Celgene over distracting ads

Regulators said the ads distract viewers from superimposed safety information.

The FDA extends deadline for off-label input

The FDA extends deadline for off-label input

The previous deadline was January 9.

Five things for pharma marketers to know: Wednesday, December 14, 2016

Five things for pharma marketers to know: Wednesday, December 14, 2016

Obama signs 21st Century Cures Act into law; the FDA approved 19 new drugs in 2016; Sanofi in talks to acquire Actelion

Eli Lilly will discount its insulins to some patients

Eli Lilly will discount its insulins to some patients

Eli Lilly partnered with Express Scripts to improve adherence for diabetes patients with high-deductible health plans.

Five things for pharma marketers to know: Tuesday, December 13, 2016

Five things for pharma marketers to know: Tuesday, December 13, 2016

Lilly to offer discounts for insulin products; Trump reportedly considering Scott Gottlieb to lead FDA; three execs depart Valeant

Chandler Chicco cofounder launches network of healthcare comms firms

Chandler Chicco cofounder launches network of healthcare comms firms

Bob Chandler retired from his role as cofounder and principal of Chandler Chicco Companies and president of InVentiv Health Communications in 2014.

Biogen recruits Jamie-Lynn Sigler for Tecfidera campaign

Biogen recruits Jamie-Lynn Sigler for Tecfidera campaign

TV actress Jamie Lynn Sigler shares her experience using the multiple-sclerosis drug in the branded campaign.

Five things for pharma marketers to know: Monday, December 12, 2016

Five things for pharma marketers to know: Monday, December 12, 2016

Generic Tamiflu estimated to generate $500 million in savings this year; ADA expected to launch new diabetes treatment guidelines; Alexion CEO resigns

MM&M launches search for 2017 Healthcare Transformers

MM&M launches search for 2017 Healthcare Transformers

It is also seeking industry input for a new category of honoree, the Top 10 Innovation Catalysts.

Merck kicks off lung-cancer campaign

Merck kicks off lung-cancer campaign

On the heels of Keytruda's approval in first-line lung cancer, the drugmaker kicked off an unbranded campaign raising awareness about biomarkers.

Five things for pharma marketers to know: Friday, December 9, 2016

Five things for pharma marketers to know: Friday, December 9, 2016

BMS to pay $19.5 million to settle marketing violations for Abilify; AstraZeneca to cut 700 U.S. jobs; Trump reportedly considering Jim O'Neill to lead FDA

How pharma can stay compliant when using programmatic

How pharma can stay compliant when using programmatic

The risk of fraud is also very real, especially in an industry that already faces privacy and compliance challenges, one expert says.

Five things for pharma marketers to know: Thursday, December 8, 2016

Five things for pharma marketers to know: Thursday, December 8, 2016

A California lawmaker reintroduces drug-pricing bill; France, Poland, Spain, and Sweden lobby to host EMA; drug stocks fall after Trump's comments

An EHR strategy can't be measured in clicks, says Lilly exec

An EHR strategy can't be measured in clicks, says Lilly exec

Pharma can reach physicians within the EHR, but they must send the right message at the right time, she said at an MM&M event.

Spectrum names Jonathan Wilson CEO

Spectrum names Jonathan Wilson CEO

Wilson will succeed founder and CEO John Seng.

W2O Group acquires Sentient Interactive

W2O Group acquires Sentient Interactive

This is W2O Group's third acquisition since a private-equity firm took an investment in May.

Senate passes Cures Act, which opens door to use of real-world evidence

Senate passes Cures Act, which opens door to use of real-world evidence

The bill now heads to President Obama's desk. He is expected to sign the sweeping piece of legislation.

Five things for pharma marketers to know: Wednesday, December 7, 2016

Five things for pharma marketers to know: Wednesday, December 7, 2016

Trump puts pharma on notice over drug prices; Mylan lays off nearly 10% of its workforce; Pfizer slapped with U.K. antitrust fine

GSK and Propeller Health's smart inhaler aims to improve adherence in clinical trials

GSK and Propeller Health's smart inhaler aims to improve adherence in clinical trials

The drugmaker is using Propeller Health's sensor technology to find new ways to improve adherence in clinical studies.

BI and Lilly face a new challenge: how to market a diabetes drug to cardiologists

BI and Lilly face a new challenge: how to market a diabetes drug to cardiologists

Boehringer Ingelheim and Eli Lilly have to position their third-in-class diabetes medication Jardiance as a heart drug.

Five things for pharma marketers to know: Tuesday, December 6, 2016

Five things for pharma marketers to know: Tuesday, December 6, 2016

Prices of Viagra and Cialis triple since 2010; AstraZeneca's Tagrisso slows lung-cancer progression compared to chemo; Novo Nordisk to limit price increases

Rock Health's Bill Evans on finding a career with meaning

Rock Health's Bill Evans on finding a career with meaning

The Roche veteran says that people who work in digital health need to touch others in a meaningful way.

Matt Brown leaves Guidemark Health after merger falls through

Matt Brown leaves Guidemark Health after merger falls through

The agency is owned by High Road Capital Partners. Sophy Regelous, the company's chief operating officer, will now lead the agency.

Five things for pharma marketers to know: Monday, December 5, 2016

Five things for pharma marketers to know: Monday, December 5, 2016

The FDA approves new indication for Jardiance; Novartis' CAR-T therapy eliminates leukemia in 82% of patients in trial; doctors report risks associated with immunotherapy

Prescription drug spending rises 9% in 2015, to $324 billion

Prescription drug spending rises 9% in 2015, to $324 billion

However, the rate of drug spending slowed compared to last year, according to an analysis by the CMS.

As users move to mobile, Google says they made 200 million queries for info about cancer drugs

As users move to mobile, Google says they made 200 million queries for info about cancer drugs

The search-engine giant says that one in 20 online searches are related to healthcare, and more users are using mobile to consume media.

Five things for pharma marketers to know: Friday, December 2, 2016

Five things for pharma marketers to know: Friday, December 2, 2016

Regeneron and Pfizer CEOs argue about the industry's reputation; Mylan CEO defends the EpiPen; Pfizer and IBM to partner on cancer immunotherapies

Mylan CEO defends EpiPen strategy, questions pricing model in the U.S.

Mylan CEO defends EpiPen strategy, questions pricing model in the U.S.

Heather Bresch's appearance at industry summit came after she declined to attend a congressional hearing scheduled for the same day.

Five things for pharma marketers to know: Thursday, December 1, 2016

Five things for pharma marketers to know: Thursday, December 1, 2016

Valeant doesn't plan to offload Salix; heart docs back Califf as commish; Saunders says pricing issues aren't affected by election

House passes 21st Century Cures Act that would allow some off-label sharing

House passes 21st Century Cures Act that would allow some off-label sharing

The bill includes two provisions that would address drugmakers' calls for clarity on sharing off-label information with payers and regulators.

MM&M's top 5 stories in November 2016

MM&M's top 5 stories in November 2016

How VR, nanotechnology, and 3D printing could improve the value of healthcare; 100 experimental therapies in late-stage clinical trials; Kite Pharma plans "controlled" launch of CAR-T therapy

Five things for pharma marketers to know: Wednesday, November 30, 2016

Five things for pharma marketers to know: Wednesday, November 30, 2016

Astellas Pharma is searching for Xtandi successor; Novo Nordisk says Tresiba is safer than Lantus; Pfizer awards Nexium account to Grey

Lilly's branded app for Trulicity looks to address adherence

Lilly's branded app for Trulicity looks to address adherence

Companies such as Eli Lilly and Medtronic have launched branded apps for their products, but experts say they don't make sense for all medicines.

Lawmakers cut CME exemption from 21st Century Cures Act

Lawmakers cut CME exemption from 21st Century Cures Act

The bill includes provisions to investigate the usefulness of off-label information but will no longer exempt drugmakers from reporting CME payments.

How Duchesnay USA got over the Kardashian marketing bump

How Duchesnay USA got over the Kardashian marketing bump

The drugmaker still views Instagram as a viable marketing platform, however.

Five things for pharma marketers to know: Tuesday, November 29, 2016

Five things for pharma marketers to know: Tuesday, November 29, 2016

Trump selects Price as head of HHS; Warren criticizes 21st Century Cures; GSK CEO says companies will have to get used to making less money

Gilead's Meyers on making deals and finding unmet patient needs

Gilead's Meyers on making deals and finding unmet patient needs

The drugmaker's new EVP of worldwide commercial operations also talks about tackling medication access, product launches, and starting a commercial team from scratch.

Five things for pharma marketers to know: Monday, November 28, 2016

Five things for pharma marketers to know: Monday, November 28, 2016

J&J in talks to buy Actelion; Novo Nordisk pulls ads on Breitbart News; Takeda to market Ninlaro in Europe

Pharma Marketers Using Programmatic, Consider Privacy and Measurement

Pharma Marketers Using Programmatic, Consider Privacy and Measurement

There's a reason pharma lags on the programmatic adoption curve: It's a heavily regulated industry, and there are concerns around privacy.

U.S. marketers spend slightly less on digital engagement with docs than China

U.S. marketers spend slightly less on digital engagement with docs than China

A new survey found that U.S. pharma marketers prefer using social media and mobile apps to reach healthcare providers.

Five things for pharma marketers to know: Wednesday, November 23, 2016

Five things for pharma marketers to know: Wednesday, November 23, 2016

Lilly's experimental Alzheimer's drug fails in another trial; two more patients die during trial for Juno's CAR-T therapy; NEJM launches platform in China

Two new therapies made by Sanofi and Novo Nordisk to compete in crowded diabetes market

Two new therapies made by Sanofi and Novo Nordisk to compete in crowded diabetes market

The FDA approved Sanofi's Soliqua and Novo Nordisk's Xultophy on Tuesday.

Infographic: The physician view on EHRs

Infographic: The physician view on EHRs

Most physicians said EHRs have negatively impacted their communication with a patients.

Five things for pharma marketers to know: Tuesday, November 22, 2016

Five things for pharma marketers to know: Tuesday, November 22, 2016

Intarcia submits diabetes drug-delivery pump for FDA approval; Shire to build rare-disease innovation hub; AstraZeneca to resume durvalumab trials

Walgreens.com to publish patient reviews of drug effectiveness

Walgreens.com to publish patient reviews of drug effectiveness

The drugstore chain added drug effectiveness reviews and other information from PatientsLikeMe to its website.

Five things for pharma marketers to know: Monday, November 21, 2016

Five things for pharma marketers to know: Monday, November 21, 2016

Novartis to delay clinical trials of contact lens for diabetes patients; the ADA calls for hearings on insulin pricing; Vice launches healthcare channel

Five things for pharma marketers to know: Friday, November 18, 2016

Five things for pharma marketers to know: Friday, November 18, 2016

Chicago requires pharma rep to have licenses, Acorda CEO backs Califf to remain FDA commish, high-prescribing medicare docs are on the rise

ContextMedia to acquire AccentHealth to grow its position in the point-of-care market

ContextMedia to acquire AccentHealth to grow its position in the point-of-care market

As part of the acquisition, 160 AccentHealth employees will join ContextMedia, which has a staff of about 500 people.

Five things for pharma marketers to know: Thursday, November 17, 2016

Five things for pharma marketers to know: Thursday, November 17, 2016

Former Valeant and Philidor execs arrested; at least 1 million enroll in 2017 exchange plans; mobile game helps scientists study dementia

Physicians still rely on medical journals but turn to the web when they have only 10 minutes

Physicians still rely on medical journals but turn to the web when they have only 10 minutes

Drugmakers can do a better job of organizing dosing information, safety information, and clinical data on their brand websites, a new survey found.

Physicians call for value-based drug pricing

Physicians call for value-based drug pricing

The largest group of U.S. physicians said drug pricing needs to align with the broader healthcare industry's drive for value.

Five things for pharma marketers to know: Wednesday, November 16, 2016

Five things for pharma marketers to know: Wednesday, November 16, 2016

The AMA votes in favor of value-based drug pricing; Amgen says insurers are balking at PCSK9 inhibitor prices; docs aren't focused on prices when prescribing

Amgen's Repatha lowers plaque in arteries

Amgen's Repatha lowers plaque in arteries

New clinical data showed that Repatha, a PCSK9 inhibitor, reduced plaque in arteries when combined with a statin.

Kite Pharma to keep anticipated CAR-T launch 'controlled' and targeted at certain hospitals

Kite Pharma to keep anticipated CAR-T launch 'controlled' and targeted at certain hospitals

"This is not your grandfather's launch," said Shawn Tomasello, chief commercial officer of Kite Pharma.

Five things for pharma marketers to know: Tuesday, November 15, 2016

Five things for pharma marketers to know: Tuesday, November 15, 2016

The CMS spent more on Harvoni than any other drug; Novartis considers selling Alcon; the EMA recommends approval of Lantus biosimilar

PulsePoint launches health vertical for programmatic advertising

PulsePoint launches health vertical for programmatic advertising

The programmatic advertising technology company also hired Chris Neuner as SVP and GM of digital health.

Pfizer expands humanitarian access to Prevnar 13 vaccine

Pfizer expands humanitarian access to Prevnar 13 vaccine

Pfizer expanded its humanitarian efforts by providing the Prevnar 13 vaccine at a low price and donating proceeds to aid groups.

OPINION

Healthcare Marketers: The Future is Personal

Email Newsletters